Novo Nordisk Jorgensen on U.S. Obesity Drugs Market
Interactive Video
•
Business
•
University
•
Hard
Wayground Content
FREE Resource
Lars Jorgensen, CEO of Novo Nordisk, discusses the company's strong business momentum driven by innovative GLP-1 products in diabetes and obesity care. He addresses the challenges of supply chain bottlenecks for the obesity drug Wegovy and outlines the eligibility criteria for its use. Jorgensen also talks about the US market's significance, drug pricing debates, and the company's support programs for patients. He concludes with insights on margin expansion and future growth strategies, emphasizing the shift from insulin to higher-margin GLP-1 products.
Read more
2 questions
Show all answers
1.
OPEN ENDED QUESTION
3 mins • 1 pt
What challenges is Novo Nordisk facing in the supply chain for their new obesity drug?
Evaluate responses using AI:
OFF
2.
OPEN ENDED QUESTION
3 mins • 1 pt
What is the company's stance on drug pricing and regulatory concerns in the US market?
Evaluate responses using AI:
OFF
Access all questions and much more by creating a free account
Create resources
Host any resource
Get auto-graded reports
Continue with Google
Continue with Email
Continue with Classlink
Continue with Clever
or continue with
Microsoft
%20(1).png)
Apple
Others
Already have an account?
